NMS-P088, a CSF-1R, FLT3 and KIT inhibitor with outstanding activity on gatekeeper resistance mutations, high tolerability, and potential for combination therapies
Elena Ardini(Nerviano Medical Sciences), Marina Ciomei(Nerviano Medical Sciences), Nilla Avanzi(Nerviano Medical Sciences), Daniele Donati(Nerviano Medical Sciences), Wilma Pastori(Nerviano Medical Sciences), Gemma Texidó(Nerviano Medical Sciences), Rachele Alzani(Nerviano Medical Sciences), Daniele Casero(Nerviano Medical Sciences), Marisa Montemartini, Luca Mancini(University of Milan), Sabrina Cribioli(Nerviano Medical Sciences), Andrea Borgia(Nerviano Medical Sciences), Arturo Galvani(Nerviano Medical Sciences), Nadia Amboldi(University of Pavia), A. Montagnoli(Technion – Israel Institute of Technology), Antonella Isacchi(Nerviano Medical Sciences)
Cited by 1
Related Papers
Discovery of drug mode of action and drug repositioning from transcriptional responses
|Proceedings of the National Academy of Sciences|2010|853
Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation
|Genes & Development|1999|611
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
|Proceedings of the National Academy of Sciences|1995|205